VEGFA and hepatocellular carcinoma: This indicates that, in addition to the effectiveness of immunotherapy combined with anti-VEGF drugs in HCC, treatments targeting TGF-β and IL-10 may also be combined with immunotherapy in the future to enhance immunotherapeutic efficacy and provide more treatment options for patients.